Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1423-0127

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model ; volume:26 ; number:1 ; day:11 ; month:11 ; year:2019 ; pages:1-14 ; date:12.2019
Journal of biomedical science ; 26, Heft 1 (11.11.2019), 1-14, 12.2019

Creator: Liou, An-Ting
Liao, Chun-Che
Chou, Shu-Fan
Chang, Ya-Shu
Chang, Chih-Shin
Shih, Chiaho

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12929-019-0585-y

URN: urn:nbn:de:101:1-2020030822404849975723

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Liou, An-Ting
Liao, Chun-Che
Chou, Shu-Fan
Chang, Ya-Shu
Chang, Chih-Shin
Shih, Chiaho
SpringerLink (Online service)

Other Objects (12)

Deoxyguanosine is a TLR7 agonist

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

Deoxyguanosine is a TLR7 agonist

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

Deoxyguanosine is a TLR7 agonist

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Deoxyguanosine is a TLR7 agonist

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

Deoxyguanosine is a TLR7 agonist

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

Deoxyguanosine is a TLR7 agonist

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod

Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

Related objects

Reset password